You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs in Registration / Phase 3

Key Biosimilars Programs in Registration / Phase 3

Key Programs in Phase 2

Pipeline date and pdf

Pipeline Snapshot as of April 30, 2019

  • Discovery Projects
  • Phase 1
    34
  • Phase 2
    30
  • Phase 3
    23
  • Registration
    10
  • Total97
 
Compound Name
Indication
Phasesort descending
Submission Type
Compound Type
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06671008
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
cadherin 3, type 1, P-cadherin (placental) (CDH3)
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06688992
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Antibody Drug Conjugate
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06753512
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Prostate Cancer Phase 1 New Molecular Entity Vaccine
PF-06755347
Therapeutic Area:
Rare Diseases
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Immunomodulation
Go to clinical trial
Chronic Inflammatory Demyelination Polyneuropathy Phase 1 New Molecular Entity Biologic
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive Group B streptococcus infection Phase 1 New Molecular Entity Vaccine
PF-06763809
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Transcription factor inhibitor
Go to clinical trial
Psoriasis Phase 1 New Molecular Entity Small Molecule
PF-06801591
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Cancer Immunotherapy (Biologic) Phase 1 New Molecular Entity Biologic
PF-06804103
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
HER2 Antibody Drug Conjugate
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06817024
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Cytokine Modulator
Go to clinical trial
Atopic Dermatitis (Biologic) Phase 1 New Molecular Entity Biologic
PF-06821497
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
EZH2 inhibitor
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06826647
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2 Inhibitor
Go to clinical trial
Inflammatory Bowel Disease Phase 1 New Molecular Entity Small Molecule
PF-06835375
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
chemokine inhibitor
Go to clinical trial
Lupus (Biologic) Phase 1 New Molecular Entity Biologic
PF-06863135
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
BCMA-CD3 Bispecific Antibody
Go to clinical trial
Multiple Myeloma (Biologic) Phase 1 New Molecular Entity Biologic
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 inhibitor
Go to clinical trial
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-06881894, a potential biosimilar to Neulasta® (Pegfilgrastim)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biosimilar
Business Segment:
Biopharma
Mechanism of Action:
Human Granulocyte Colony Stimulating Factor
Go to clinical trial
Neutropenia in patients undergoing cancer chemotherapy (Biosimilar) Phase 1 Biosimilar Biosimilar
PF-06865571
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) Phase 1 New Molecular Entity Small Molecule
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRDM
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY meningococcal infections Phase 1 New Molecular Entity Vaccine